US 11,654,120 B2
Composition for treating skin conditions
Marshall Ollie Almarode, Pasco, WA (US)
Assigned to OLLIE'S HEALTH, LLC, Pasco, WA (US)
Appl. No. 16/324,265
Filed by OLLIE'S HEALTH, LLC, Pasco, WA (US)
PCT Filed Aug. 10, 2017, PCT No. PCT/US2017/046311
§ 371(c)(1), (2) Date Feb. 8, 2019,
PCT Pub. No. WO2018/031783, PCT Pub. Date Feb. 15, 2018.
Claims priority of provisional application 62/373,921, filed on Aug. 11, 2016.
Prior Publication US 2019/0183814 A1, Jun. 20, 2019
Int. Cl. A61K 31/122 (2006.01); A61K 36/11 (2006.01); A61K 31/355 (2006.01); A61K 31/375 (2006.01); A61K 31/728 (2006.01); A61K 36/05 (2006.01); A61Q 19/08 (2006.01); A61K 8/9789 (2017.01); A61K 8/35 (2006.01); A61Q 19/00 (2006.01); A61K 8/9741 (2017.01); A61K 31/4188 (2006.01); A61K 31/7048 (2006.01); A61K 36/15 (2006.01); A61K 36/74 (2006.01); A61K 38/39 (2006.01); A61K 9/00 (2006.01); A61P 17/02 (2006.01); A61Q 17/04 (2006.01)
CPC A61K 31/122 (2013.01) [A61K 8/35 (2013.01); A61K 8/9741 (2017.08); A61K 8/9789 (2017.08); A61K 9/0014 (2013.01); A61K 31/355 (2013.01); A61K 31/375 (2013.01); A61K 31/4188 (2013.01); A61K 31/7048 (2013.01); A61K 31/728 (2013.01); A61K 36/05 (2013.01); A61K 36/11 (2013.01); A61K 36/15 (2013.01); A61K 36/74 (2013.01); A61K 38/39 (2013.01); A61P 17/02 (2018.01); A61Q 17/04 (2013.01); A61Q 19/00 (2013.01); A61Q 19/004 (2013.01); A61Q 19/08 (2013.01); A61K 2800/522 (2013.01); A61K 2800/92 (2013.01)] 13 Claims
 
1. A composition for administering to a subject with skin cancer, skin damage, or inflammation comprising:
Polypodium leucotomos extract;
Hyaluronic acid;
Astaxanthin; and
a mixture of (a) Cat's claw extract, Collagen type II, Hesperidin, Horse tail extract, Vitamin C, Vitamin E, and biotin or (b) Pine bark extract, Collagen type II, Hesperidin, Horse tail extract, Vitamin C, Vitamin E, and biotin;
wherein the mass ratio of Polypodium leucotomos extract: Astaxanthin is about 100:1 to about 10:1; and
wherein the mass ratio of Astaxanthin:Hyaluronic acid is about 1:100 to about 1:10.